Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,600JPY
23 May 2018
Change (% chg)

-- (--)
Prev Close
¥4,600
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,087,754
52-wk High
¥6,693
52-wk Low
¥4,398

Select another date:

Thu, May 17 2018

Photo

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

* Takeda boss to raise bar for pipeline drugs after Shire deal

Takeda sees lower annual profit, generics to erode cancer drug sales

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent drop in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to face generic competition in the United States.

UPDATE 2-Takeda sees lower annual profit, generics to erode cancer drug sales

* Takeda looking to strengthen pipeline by acquiring Shire (Adds executive comment, details)

Takeda posts 55 pct jump in annual profit, beats estimates

TOKYO, May 14 Japan's Takeda Pharmaceutical Co Ltd reported on Monday a 55.1 percent jump in annual operating profit, buoyed by growing sales of bowel disease drug Entyvio and heartburn and ulcer drug Takecab.

Takeda smashes Asian loan record

* Loans: JP Morgan leads US$30.85bn bridge for Shire acquisition

Japan's Takeda clinches $62 billion Shire deal as pharma M&A rolls on

LONDON/TOKYO Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. | Video

Japan's Takeda clinches $62 billion Shire deal as pharma M&A rolls on

LONDON/TOKYO Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. | Video

Breakingviews - Takeda swallows big dose of risk to buy Shire

LONDON (Reuters Breakingviews) - Takeda Pharmaceutical is swallowing a big dose of risk to buy Shire. The Japanese drugmaker finally struck a deal to take control of its Irish peer, for $62 billion. It can just about make the math work, but requires big spending cuts and a load of debt.

Select another date: